Animal NDC 50989-892-17 Veterinary Vedalyte
Sodium Chloride, Sodium Gluconate, Sodium Acetate Trihydrate, Potassium Chloride, Magnesium Chloride
Animal Product Information
Field Name | Field Value |
---|---|
Animal NDC Code | 50989-892-17 |
Proprietary Name | Veterinary Vedalyte What is the Proprietary Name? The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes. |
Non-Proprietary Name | Sodium Chloride, Sodium Gluconate, Sodium Acetate Trihydrate, Potassium Chloride, Magnesium Chloride What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product. |
Labeler Name | Vedco, Inc. |
Product Type | Prescription Animal Drug |
Usage Information |
|
Active Ingredient(s) |
|
Marketing Category | UNAPPROVED DRUG OTHER What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Veterinary Vedalyte Animal Product Labeling Information
The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.
Table of Contents
Other
For Animal Use Only
Description
Veterinary VEDALYTE 7.4 Injection, USP is a sterile, nonpyrogenic isotonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. It contains no antimicrobial agents or preservatives. Discard unused portion. The pH is adjusted with sodium hydroxide. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1:
Clinical Pharmacology
Veterinary VEDALYTE 7.4 Injection, USP administered intravenously has a value as a source of water, electrolytes and calories. Normal physiological osmolarity range is 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions may cause vein damage. It is capable of inducing diuresis, depending on the clinical condition of the patient.
Veterinary VEDALYTE 7.4 Injection, USP produces a metabolic alkalinilizing effect. Acetate and gluconate ions are metabolized ultimately to carbon dioxide and water, which requires consumption of hydrogen cations
Indications And Usage
Veterinary VEDALYTE 7.4 Injection, USP is indicated as a source of water and electrolytes or as an alkalinizing agent
Veterinary VEDALYTE 7.4 Injection, USP is compatible with blood or blood components. it may be administered prior to or following the infusion of blood through the same administration set (i.e. as a primary solution), added to or infused concurrently with blood components or used a diluent in the transfusion of packed erythrocytes. VEDALYTE 7.4 Injection, USP and 0.9% Sodium Chloride Injection, USP are equally compatible with blood or blood components
Contraindications
None Known
Warnings
Veterinary VEDALYTE 7.4 Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.
Veterinary VEDALYTE 7.4 Injection, USP should be used with great care, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.
Veterinary VEDALYTE 7.4 Injection, USP should be used with great care, in patients with metabolic or respiratory alkalosis. The administration of acetate or gluconate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.
The intravenous administration of Veterinary VEDALYTE 7.4 Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.
In patients with diminished renal function, administration of lactated Ringer's Injection, USP may result in sodium or potassium retention.
Adverse Reaction
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Precautions
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
VETERINARY VEDALYTE 7.4 Injection,USP must be used with caution. Excess administration may result in metabolic alkalosis.
Caution must be exercised in the administration of VETERINARY VEDALYTE 7.4 Injection, USP to patients receiving corticosteroids or corticotrophin.
Do not administer unless solution is clear and seal is intact.
Dosage And Administration
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient, as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique.
Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
Overdosage
In an event of over hydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See Warnings. Precautions and Adverse Events.
How Supplied
Veterinary VEDALYTE 7.4 Injection, USP in plastic container is available as follows:
Plastic Container:
*PVC Free, DEHP Free, Latex Free Bag.
** The plastic container is fabricated from a specially formulated polyvinyl chloride. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), upto 5 parts per million. However safety of the plastic has been confirmed in animals according to USP biological tests for plastic containers, as well as tissue culture toxicity studies.
Storage
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored in the moisture overwrap at room temperature (25°C/77°F); brief exposure up to (40°C/104°F) does not adversely affect the product.
Direction For Use Of Plastic Section
To Open
Tear
overwrap down side at slit and remove solution container. Some opacity
of the plastic due to moisture absorption during the sterilization
process may be observed. This is normal and does not affect the
solution quality or safety. The opacity will diminish gradually. Check
for minute leaks by squeezing inner bag firmly. If leaks are found,
discard solution as sterility may be impaired. If supplemental
medication is desired, follow directions below.
Preparation for Administration
1. Suspend container from eyelet support.
2. Remove protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.
To Add Medication
WARNING: Additives may be incompatible.
To add medication before solution administration
1. Prepare medication site.
2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
To add medication during solution administration
1. Close clamp on the administration set to stop flow to the patient.
2. Prepare medication site.
3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
4. Remove container from IV pole and/or turn to an upright position.
5. Evacuate both ports by squeezing them while container is in the upright position.
6. Mix solution and medication thoroughly.
7. Return container to in-use position and continue administration.
CAUTION: Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.
Manufactured for
Vedco, Inc.
5503 Corporate Dr.
St. Joseph, MO 64507 USA
Printed in El Salvador
For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Vedco, Inc. customer service at 1(888) 708-3326
VEDALYTE is a trademark of Vedco INc., all rights reserved.
© 2016 Vedco, Inc.
Principal Display Panel
NDC 50989-892-16
BIOGALENIC VEDCO
VETERINARY VEDALYTE 7.4 INJECTION, USP
NDC 50989-892-17
BIOGALENIC VEDCO
VETERINARY VEDALYTE 7.4 INJECTION, USP
* The information on this page is for an ANIMAL PRODUCT, please review the complete disclaimer below.